Komipharm International코미팜

Komipharm's 2026 first-half operating profit is small and it still posts a net loss, with shares well off their 52-week high.

Komipharm, a Korean veterinary vaccine maker also developing the cancer-pain drug PAX-1, reported trailing twelve-month revenue of ₩53B-scale... specifically ₩53.0B, an operating profit of ₩1.8B and a net loss of ₩2.6B. Shares closed at ₩8,290 on 27 October 2026, about 30% below the 52-week high of ₩11,890 but still up 34.1% over one year.

What stands out

• Trailing revenue of ₩53.0B is roughly flat versus 2025's ₩52.5B, after 2024's ₩58.8B peak.
• Operating margin is thin at 3.3% on a trailing basis, and the company is still loss-making at the net line (net margin -4.9%).
• Free cash flow was negative at about ₩-2.4B, and borrowings of ₩40.8B exceed cash of ₩21.4B.
• The company pays no dividend, and the price-to-book ratio of 8.6 is high against its recent return on equity of -3.9%.
• Foreign ownership rose from 3.6% to 4.8% over about 60 days, while institutions were net sellers over the last 20 days.

What to watch

• Next quarterly and full-year results, to see whether operating profit holds and the net loss narrows.
• Filings on the major sales or supply contract, which were amended in April and September 2026; the amendment details are not in the data.
• Progress of PAX-1 clinical trials, which the data mentions but gives no timeline or results for.